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Introduction: The prognostic significance of activity biomarkers 
within the phosphatidylinositol 3-kinase (PI3K)/mammalian target 
of rapamycin (mTOR) signaling pathway was assessed in two inde-
pendent cohorts of malignant pleural mesothelioma (MPM) patients 
uniformly treated with a multimodal approach. We specifically 
assessed expression signatures in a unique set of pre- and postchemo-
therapy tumor samples.
Methods: Biomarker expression was assessed in samples of two 
independent cohorts of 107 (cohort 1) and 46 (cohort 2) MPM cases 
uniformly treated with platinum-based induction chemotherapy 
followed by extrapleural pneumonectomy from two different insti-
tutions, assembled on tissue microarrays. Expression levels of phos-
phatase and tensin homologue (PTEN), phospho-mTOR, and p-S6 
in addition to marker of proliferation (Ki-67) and apoptosis (cleaved 
caspase-3) were evaluated by immunohistochemistry and correlated 
with overall survival (OAS) and progression-free survival (PFS). To 
assess PTEN genomic status, fluorescence in situ hybridization was 
performed.
Results: Survival analysis showed that high p-S6 and Ki-67 expres-
sion in samples of treatment naïve patients of cohort 1 was associated 
with shorter PFS (p = 0.02 and p = 0.04, respectively). High Ki-67 
expression after chemotherapy remained associated with shorter 
PFS (p = 0.03) and OAS (p = 0.02). Paired comparison of marker 
expression in samples before and after induction chemotherapy of 
cohort 1 revealed that decreased cytoplasmic PTEN and increased 
phospho-mTOR expression was associated with a worse OAS 
(p = 0.04 and p = 0.03, respectively).
Conclusions: These novel data reveal a prognostic significance of 
expression changes of PI3K/mTOR pathway components during 
induction chemotherapy if confirmed in other patient cohorts and 
support the growing evidence to target the PI3K/mTOR pathway in 
the treatment of MPM.
Key Words: Phosphatidylinositol 3-kinase/mammalian target of 
rapamycin, Phosphatase and tensin homologue, Ki-67, Mesothelioma, 
Multimodality treatment.
(J Thorac Oncol. 2014;9: 239–247)
Malignant pleural mesothelioma (MPM) is a rare and aggressive asbestos-related tumor,1–3 with a median sur-
vival of 12 months or less without treatment.4–6 Multimodal 
therapy including macroscopic complete resection is currently 
suggested for mesothelioma patients tailored to the patient’s 
requirements and the stage of the disease.7 One particular 
approach with promising survival data involves induction che-
motherapy followed by extrapleural pneumonectomy (EPP).8,9 
Not all patients benefit from this treatment approach. Therefore, 
the identification of prognostic markers that may help in select-
ing patients remains a subject of key importance.10
In recent years, the phosphatidylinositol 3-kinase 
(PI3K)/mammalian target of rapamycin (mammalian target of 
rapamycin [mTOR]) pathway has been the focus of interest for 
identifying potential prognostic markers for cancer.11–13 The 
PI3K/mTOR signaling pathway is activated by the binding of 
growth factors to cell surface receptor tyrosine kinases and as 
such is charged with integrating nutrient and energy homeo-
stasis with mitogenic input.13 Activation of the PI3K/mTOR 
pathway results in the regulation of cell growth, protein bio-
synthesis, and proliferation, all of which promote tumori-
genesis.12 Signaling of this pathway is however negatively 
regulated by the tumor suppressor phosphatase and tensin 
homologue (PTEN).14 Accordingly, up-regulation of the PI3K/
mTOR pathway, often through loss of PTEN function, has 
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been detected in a variety of neoplasms including prostate,15,16 
breast,17 and colorectal cancer18 in addition to malignant 
melanoma19 and has subsequently been targeted for thera-
peutic intervention.12 Indeed, molecules targeting the PI3K/
mTOR pathway have been developed and are currently being 
evaluated in various cancer clinical trials20,21 including MPM 
(ClinicalTrials.gov Identifier: NCT01024946—Everolimus 
study).12
By using a tissue microarray (TMA)–based approach in 
a previous study, we observed a loss of PTEN protein in 62% 
of mainly untreated MPM patients.22 A recent study by Cedrés 
et al.23 confirmed that aberrant activation/expression in some 
constituent proteins of the PI3K/mTOR signaling cascade pro-
vides prognostic information in treatment-naïve patients with 
MPM. The present study therefore aimed to further elucidate 
the prognostic significance of the PI3K/mTOR signaling path-
way in clinically annotated samples from two independent 
cohorts of MPM patients uniformly treated in a multimodal 
treatment concept. In this unique cohort of MPM patients, we 
specifically sought to identify the prognostic value of activ-
ity biomarkers of the PI3K/mTOR pathway in tumor samples 
collected before and after induction chemotherapy to define 
selection criteria for multimodality treatment.
PATIENTS AND METHODS
Patients
In this study, we included two independent cohorts 
(University Hospital Zurich, cohort 1, 1999–2009 [n = 107]; 
Toronto General Hospital, cohort 2, 2001–2011 [n = 46]) of 
MPM patients uniformly treated with induction chemotherapy 
followed by EPP as described previously.8,24 The study was 
approved, and waivers of consent were granted by the Ethical 
Committee Zürich (StV 29–2009 and EK-ZH 2012-0094) 
and by an Institutional Ethical Review Board at the Toronto 
General Hospital (IRB No. 11-0167-T).
TMA Construction and Immunohistochemistry
A set of four TMAs with double prechemotherapy and 
quadruple postchemotherapy punches per patient was prepared 
with a custom-made, semiautomatic tissue arrayer (Beecher 
Instruments, Sun Prairie, WI), as previously described.25 
Recipient TMA blocks were sectioned and stained with hema-
toxylin and eosin for morphologic assessment. Technical 
factors leading to loss of patient material during TMA pro-
cessing (i.e., sectioning and staining) may be reflected through 
a reduction in the patient numbers available for subsequent 
statistical analysis.
Deparaffinized 2-μm-thick TMA sections were automat-
ically stained with BenchMark (Ventana, Tucson, AZ) using the 
iView diamino benzidine detection kit (Ventana). The primary 
antibodies were a mouse monoclonal antibody (Novocastra, 
Newcastle, United Kingdom) for PTEN (28H6) diluted at 
1:200, rabbit polyclonal antibodies (Cell Signaling Technology, 
Danvers, MA) against phospho-S6 (p-S6, Ser240/244) at a 
1:50 dilution, a rabbit monoclonal antibody (Cell Signaling 
Technology) for phospho-mTOR (p-mTOR, 49F9) at a 1:50 
dilution, rabbit polyclonal antibodies (Abcam, Cambridge, 
United Kingdom) against cleaved (active) caspase-3 at a 1:50 
dilution, and a rabbit monoclonal antibody (Ventana Roche, 
Tucson, AZ) for Ki-67 (30–9) at a 1:50 dilution.
Immunohistochemical evaluation of the TMAs was 
conducted by four independent observers (B.B., M.M., S.T., 
and L.F.) in a blinded manner and cross-checked by a senior 
pathologist (A.S.). The staining intensity was semiquanti-
tatively scored 0 (negative), 1 (weak), 2 (moderate), or 3 
(strong). Furthermore, the percentage of cells having any pos-
itivity was proportionally scored 0 (0%), 0.1 (1%–9%), 0.5 
(10%–49%), or 1.0 (50% and more) as previously described.26 
The H-score was obtained by multiplication of intensity with 
percentage staining (final range, 0 to 3, per core). The final 
H-score was determined by averaging the H-scores of all the 
cores from the same patient.
The proliferation and apoptotic indices were defined as 
the percentage of Ki-67 and cleaved caspase-3–positive tumor 
cells, respectively, in representative tumor areas or hot spots. 
Hot spots are areas of tumor that exhibit higher levels of prolif-
eration or apoptosis than the rest of the tumor areas.27,28 In each 
core, the amount of cells with nuclear Ki-67 immunostaining or 
which exhibited cellular cleaved caspase-3 expression among 
100 tumor cells was carefully counted (i.e., the proliferation or 
apoptotic index = proliferation or apoptotic cell count/total cell 
count × 100%). The overall proliferation and apoptotic indices 
were calculated by summing the percentage of positive cells 
obtained from each core and dividing this value by the total 
number of cores assessed from each MPM patient.
Fluorescence In Situ Hybridization 
Probe Selection and Analysis
Fluorescence in situ hybridization (FISH) was con-
ducted on a single 4-μm-thick postchemotherapy TMA sec-
tion using the Vysis LSI PTEN (10q23)/CEP 10 Dual Color 
Probe (Abbott Molecular Inc., Abbott Park, IL) according 
to the manufacturer’s description. Ten MPM patients from 
cohort 1 with high PTEN expression scores (H-score >2) and 
10 patients from cohort 1 with low PTEN protein expression 
(H-score <1) were selected for PTEN analyses. FISH analysis 
was performed in a blinded manner using a section immedi-
ately adjacent to the first hematoxylin and eosin–stained slide 
to verify the presence of tumor. Samples were analyzed under 
a 100× oil immersion objective, using an Olympus BX-UCB 
fluorescence microscope equipped with appropriate filters, a 
 charge-coupled device camera and the CytoVision FISH imag-
ing and capturing software (Applied Imaging, San Jose, CA). 
Semiquantitative evaluation of the tests was independently 
performed by B.B. and cross-checked by a senior pathologist 
(A.S.). For each case, an attempt was made to analyze at least 
100 well-delineated tumor cells. PTEN genomic status was 
assessed by comparing the number of (orange) PTEN probe 
signals with the number of (green) reference signals (CEP-10 
probe specifically hybridizes alpha satellite sequences specific 
to centromere region of chromosome 10). Infiltrating lympho-
cytes (from within the tumor core biopsies) were used as a ref-
erence for determining cutoff values (i.e., mean percentage + 
three SDs29; see Supplementary Table 1, Supplemental Digital 
Content 1, http://links.lww.com/JTO/A499).
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Statistical Analysis
The expression of the different markers before and/or 
after chemotherapy and the dynamic change during chemo-
therapy were assessed for their prognostical impact on over-
all survival (OAS) and progression-free survival (PFS) and 
were correlated to histological subtype, modified Response 
Evaluation Criteria in Solid Tumors (RECIST) criteria, pT 
or pN stage, and International Mesothelioma Interest Group 
(IMIG) stages. The cutoff values were defined based on 
the median score of the tumor samples undergoing similar 
treatment (i.e., prechemotherapy and postchemotherapy). 
Protein expression values above the median were classi-
fied as High, whereas protein expression values below the 
median were classified as Low. TMA spots with a lack of 
tumor tissue (sampling error), damaged tissue (heat or crush 
artifact), or a total lack of tissue at some array positions 
(empty spots) were excluded from the analysis, leading to 
different patient numbers in the subsequent analysis. Tumor 
response to treatment was evaluated based on modified 
RECIST criteria.30 OAS was defined as time between appli-
cation of the first cycle of chemotherapy and time point of 
death or last follow-up. PFS was defined as the time interval 
between start of the first cycle of chemotherapy and pro-
gression based on the first confirmed sign of disease being 
either evident clinically, histologically confirmed by biopsy 
or  fine-needle aspiration or evident radiologically with 
increasing tumor masses on regular follow-up computed 
tomography scans. Median survival time was assessed by 
Kaplan–Meier curves, and the influence of the different 
prognostic factors was analyzed by log rank test. p values 
lower than 0.05 were considered statistically significant. All 
analyses were carried out using IBM SPSS Statistics, ver-
sion 20 (SPSS Inc., Chicago, IL).
RESULTS
Patient Characteristics of the 
Two Study Cohorts
The characteristics of MPM patients in the two cohorts 
are summarized in Table 1. In both cohorts, the median age of 
MPM patients was 61, mostly males were affected (92% cohort 
1 versus 80% cohort 2), and the most frequent tumor histotype 
was epithelioid (54% cohort 1 versus 78% cohort 2). Patients 
with IMIG stage III to IV were more frequent in cohort 2 (i.e., 
64% cohort 1 versus 87% cohort 2). Prechemotherapy tissue 
samples were only available from cohort 1 (n = 87), whereas 
postchemotherapy samples were available in both cohort 1 
(n = 106) and cohort 2 (n = 46). Paired samples with tissue 
before and after chemotherapy were available in 86 patients 
from cohort 1.
Expression Pattern of PTEN, p-S6, p-mTOR, 
Ki-67, and Cleaved Caspase-3 in MPM Tissue
PTEN protein was homogeneously expressed in both 
the cytoplasmic and nuclear compartments (Fig. 1B and F), 
whereas p-S6 (Fig. 1C and G) and p-mTOR (Fig. 1D and H) 
expression was mostly restricted to the cytoplasm of tumor 
cells. Notably, increased p-mTOR and p-S6 protein expression 
was detected within the tumor cells compared with the fibro-
blasts of the surrounding stroma (Fig. 1). Although Ki-67 
expression was restricted to the nucleus, cleaved caspase-3 
expression was located in both the nuclear and cytoplasmic 
cellular fractions.
A significant reduction in PTEN H-score (cytoplasmic, 
p = 0.04 and nuclear, p < 0.0005) was detected after che-
motherapy in cohort 1 (n = 75) where biopsies were avail-
able before and after chemotherapy (Fig. 2). Similar levels 
of nuclear and cytoplasmic PTEN expression were observed 
after chemotherapy in cohort 2 (Supplementary Figure 1, 
Supplemental Digital Content 2, http://links.lww.com/JTO/
A500). A significantly reduced expression profile was also 
observed for p-mTOR in tumor tissue collected after induction 
chemotherapy (n = 66; p < 0.0005), p-S6 (n = 72; p < 0.0005), 
and Ki-67 (n = 69; p < 0.0005) in cohort 1. As opposed to 
the other four markers, a significantly increased expression of 
cleaved caspase-3 was detected after chemotherapy (n = 74; 
p = 0.03) in cohort 1 (Fig. 2).
TABLE 1.  Patients Characteristics
Cohort 1 Cohort 2 p
No. of patients 107 46
Follow-up (months) 22 (3–121) 15 (4–115)
Median age 61 (36–72) 61 (33–78) 0.9a
Sex 0.06a
  Male 98 (92%) 37 (80%)
  Female 9 (8%) 9 (20%)
Induction chemotherapy
  Cisplatin/gemcitabine 46 (43%) 6 (13%)
  Cisplatin/pemetrexed 58 (54%) 18 (39%)
  Other 3 (3%) 22 (48%)
Adjuvant radiotherapy 62 (58%) 37 (80%)
Histological features 0.02a
  Epithelioid 57 (53%) 36 (78%)
  Sarcomatoid 5 (5%) 0
  Biphasic 45 (42%) 10 (22%)
Tumor stage (IMIG) 0.003a
  I 10 (9%) 1 (2%)
  II 29 (27%) 5 (11%)
  III 58 (55%) 27 (59%)
  IV 10 (9%) 13 (28%)
pT stage 0.001
  ypT 1 10 (9%) 1 (2%)
  ypT 2 40 (38%) 7 (15%)
  ypT 3 47 (44%) 25 (54%)
  ypT 4 10 (9%) 13 (29%)
pN stageb 0.02
  ypN 0 70 (66%) 20 (44%)
  ypN 1 14 (13%) 8 (17%)
  ypN 2 22 (21%) 17 (37%)
  ypN 3 1 (2%)
aSignificance was calculated with the Student’s t test and the Fisher’s exact test.
bData were not available for all 107 patients.
IMIG = International Mesothelioma Interest Group.
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Prognostic Value of p-S6, PTEN, p-mTOR, 
Ki-67, and Cleaved Caspase-3 Expression
A significant association was found between the pre-
chemotherapy expression level of p-S6 and Ki-67 with 
PFS (p = 0.02, n = 75 and p = 0.04, n = 74, respectively). 
Specifically, low expression of p-S6 was associated with 
longer PFS as opposed to high p-S6 expression (Fig. 3A). 
Similarly, low level of Ki-67 was found to be associated with 
a longer PFS as opposed to high Ki-67 levels (Fig. 3B).
Moreover, low expression levels of Ki-67 in postchemo-
therapy tissue was found to be associated with a longer PFS 
(p = 0.03, n = 101; Fig. 3C) and OAS (p = 0.02, n = 101; 
Fig. 3D, respectively).
In contrast, no significant association was detected 
between pre- and postchemotherapy biopsy expression levels 
of PTEN (nuclear and cytoplasmic), p-mTOR, and cellular 
cleaved caspase-3 with either OAS or PFS.
To assess the value of the dynamic changes observed dur-
ing chemotherapy, we applied a paired sample analysis in which 
we compared the expression levels of the markers of interest 
(i.e., PTEN, p-mTOR, p-S6, Ki-67, and cleaved caspase-3) 
pre- and postchemotherapy of cohort 1. Survival analysis indi-
cated that a reduction in cytoplasmic expression of PTEN was 
significantly associated with shorter OAS (p = 0.04, n = 75; 
Fig. 3E) but not PFS. Increased expression of p-mTOR had a 
significant prognostic impact on shorter OAS (p = 0.03, n = 66; 
Fig. 3F) but not on PFS. In contrast to PTEN and p-mTOR, no 
significant association between the relative expression of p-S6, 
 caspase-3, and Ki-67 with OAS or PFS was detected.
There was no significant association between expression 
of the different markers in pre- or postchemotherapy expres-
sion and the clinico-pathological variables including histo-
logical subtype, modified RECIST criteria, pT or pN stage, 
and IMIG stages (data not shown). Similarly, the dynamic 
changes in marker expression did not correlate with any of the 
 clinico-pathological variables.
PTEN FISH Assessment
To determine whether the reduction in PTEN protein 
expression observed in MPM patients after induction che-
motherapy was owing to gene deletion, PTEN FISH was per-
formed on a subset of these cases (i.e., MPM patients who 
either had high [H-score >2] or low [H-score <1] PTEN pro-
tein expression). None of the MPM cases evaluated showed 
PTEN hemizygous or homozygous deletion. Therefore, there 
was no correlation between PTEN protein expression level 
and PTEN FISH status (data not shown)
DISCUSSION
We have demonstrated a prognostic significance of the 
PI3K/mTOR signaling pathway for patients undergoing a mul-
timodal treatment concept using a TMA-based approach in 
FIGURE 1.  Immunohistochemical staining of PTEN, p-S6, and p-mTOR in MPM in an epithelioid subtype. Hematoxylin 
and eosin staining of respective MPM cores (A and E). Cytoplasmic and nuclear PTEN expression (B—strong and F—Weak). 
Cytoplasmic expression of p-S6 (C—strong and G—weak). Cytoplasmic expression of p-mTOR (D—strong and H—weak). 
Cyto = cytoplasm; Nuc = nucleus; PTEN, phosphatase and tensin homologue; p-mTOR, phospho-mammalian target of 
 rapamycin; MPM, malignant pleural mesothelioma.
243Copyright © 2013 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 9, Number 2, February 2014 PI3K/mTOR Signaling in Mesothelioma Patients
two independent cohorts of MPM patients uniformly treated 
with induction chemotherapy followed by EPP. As a new find-
ing, we observed that a decrease in PTEN and an increase 
in p-mTOR expression during induction chemotherapy were 
associated with shorter OAS; this seems to become particu-
larly important on the long term after 12 months survival and 
longer. To our knowledge, this is the first study to investigate 
whether dynamic changes in biomarkers of activity within the 
PI3K/mTOR signaling pathway during induction chemother-
apy influence MPM patients’ survival.
We observed that PTEN levels were reduced after 
 cisplatin-based induction chemotherapy both in the cytoplasm 
and the nucleus. Although the role of cytoplasmic PTEN to 
dampen the activity of the PI3K/mTOR pathway has been well 
documented,14 the function of nuclear PTEN is gradually being 
unraveled.31 Nuclear PTEN plays a role in DNA repair,32 cell 
cycle arrest,33 chromosome stability,32 and tumor-suppressive 
activity.34 The balance between the functions of these two cel-
lular fractions of PTEN is an important factor in determin-
ing whether a cell remains benign or becomes neoplastic.31 
Although we observed a reduction in nuclear PTEN expression 
after induction chemotherapy, only the cytoplasmic expression 
of PTEN seemed to be associated with clinical outcome, stress-
ing the role of PI3K/mTOR signaling in MPM progression.
The observed decrease in PTEN immunoreactivity after 
chemotherapy was unexpected. Although Krisman et al.35 have 
reported genomic loss at the PTEN locus in MPM patients, 
in the current study we found no deletion, meaning that the 
reduction in the PTEN protein expression after chemotherapy 
is probably because of other mechanisms such as transcrip-
tion regulation and protein destabilization.36 This is not the 
first time that a decrease in biomarker expression has been 
observed after chemotherapy as similar changes have recently 
been reported in breast cancer.37 We have previously reported 
loss of PTEN expression to be associated with shorter OAS.22 
In the present study, approximately 25% of MPM patients 
who underwent examination in both cohorts exhibited low 
PTEN expression (i.e., H-score 0–1.00). Agarwal et al.38 
have recently demonstrated in a set of 86 archival samples 
of untreated MPM patients that PTEN is absent in 26.7% 
of the patients when compared with expression in normal 
pleura. Cedrés et al.23 reported 10% PTEN loss in the cyto-
plasmic fraction in archive biopsies of chemonaïve patients. 
Consistent with the aforementioned studies, we found no sig-
nificant association between PTEN expression and survival in 
the present series of MPM patients. Potential explanations for 
these disparities may be differences in scoring methods and 
the MPM populations. Indeed, although in the present study 
FIGURE 2.  Box and whisker plots of expression 
levels of PTEN (cytoplasmic and nuclear), p-S6, 
p-mTOR, Ki-67, and cleaved caspase-3 in paired 
MPM data sets from pre- and postchemotherapy 
(CTX) biopsies. A, Expression levels (H-score) 
of cytoplasmic PTEN (p = 0.04), nuclear PTEN 
(p < 0.0005), p-S6 (p < 0.0005), and p-mTOR 
(p < 0.0005) were significantly reduced after 
CTX. B, Ki-67 proliferation index was significantly 
reduced after CTX (p < 0.0005). C, Apoptotic 
index by means of cleaved caspase-3–positive 
tumor fractions was significantly increased after 
CTX (p = 0.03). Significance was calculated with 
related-samples Wilcoxon signed-rank test. PTEN, 
phosphatase and tensin homologue; p-mTOR, 
phospho-mammalian target of rapamycin; MPM, 
malignant pleural mesothelioma.
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FIGURE 3.  Kaplan–Meier curves according to PTEN, p-mTOR, p-S6, Ki-67, and cleaved caspase-3 expression levels in 
 malignant pleural mesothelioma tissue samples. A, High p-S6 expression before chemotherapy (CTX) is associated with shorter 
PFS: patients with low to moderate p-S6 expression (median PFS = 16 months, 95% CI, 12–21, versus high p-S6 = 12 months, 
95% CI, 5–18) (cohort 1, n = 75); Kaplan–Meier estimates of median time to progression (log rank test: p = 0.02). B, High 
Ki-67 proliferation index before chemotherapy is significantly associated with shorter PFS (low to moderate Ki-67 = 18 months, 
95% CI, 13–23, against high Ki-67 = 12 months, 95% CI, 10–13) (cohort 1, n = 74); Kaplan–Meier estimates of median time 
to progression (log rank test: p = 0.04). C, Ki-67 proliferation index after chemotherapy is significantly associated with shorter 
PFS (low to moderate Ki-67 = 16 months, 95% CI, 10–21, against high Ki-67 = 14 months, 95% CI, 10–17) (cohort 1 n = 101); 
Kaplan–Meier estimates of median time to progression (log rank test: p = 0.03). D, High Ki-67 proliferation index after che-
motherapy is significantly associated with shorter OAS (low to moderate nuclear Ki-67 = 22 months, 95% CI, 17–27 months, 
against high Ki-67 = 20 months, 95% CI, 15–25 months) (cohort 1 n = 101); Kaplan–Meier estimates of OAS (log rank test: 
p = 0.02). E, Reduced cytoplasmic PTEN expression is significantly associated with shorter OAS (decreased PTEN = 19 months, 
95% CI, 13–24 months, against increased PTEN = 23 months, 95% CI, 16–30 months) (cohort 1 n = 75); Kaplan–Meier 
 estimate for OAS (log rank test: p = 0.04). F, Increased cytoplasmic p-mTOR expression is significantly associated with shorter 
OAS (decreased p-mTOR = 23 months, 95% CI, 18–28, against increased p-mTOR = 11 months, 95% CI, 5–17 months) 
(cohort 1 n = 66); Kaplan–Meier estimate for OAS (log rank test: p = 0.03). PFS, progression-free survival; OAS, overall survival; 
PTEN, phosphatase and tensin homologue; CI, confidence interval.
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biopsies were collected from MPM patients before or after 
induction chemotherapy, our original study was mainly com-
posed of biopsies from MPM patients collected at autopsy 
(77%). Interestingly, PTEN expression has been reported to 
be reduced in advanced stages of prostate cancer39 and in late-
stage non–small-cell lung cancer compared with  early-stage 
biopsies.40 Even though PTEN expression was not signifi-
cantly correlated with the IMIG stage in the MPM patients 
analyzed herein, we noted a trend toward a reduction in PTEN 
expression with increased IMIG stage (data not shown).
mTOR is a highly conserved serine/threonine kinase 
and a central regulator of cell growth and metabolism in 
eukaryotes.13 Our data did not reveal any association between 
p-mTOR immunoreactivity in the pre- and postchemotherapy 
biopsies and survival when they were analyzed indepen-
dently. Consistent with these findings, Cedrés et al.23 have also 
reported no significant correlation between p-mTOR expres-
sion levels and survival in their cohort of  chemotherapy-naïve 
MPM patients. Nevertheless, the observed decrease in 
p-mTOR expression after chemotherapy and its prognostic 
significance indicate that mTOR activation is modified by the 
treatment and that this change influences clinical outcome. 
Against this background, the administration of mTOR inhibi-
tors to MPM patients who exhibit increased p-mTOR after 
chemotherapy treatment may be beneficial.
An integral downstream target of the PI3K/mTOR sig-
naling pathway is the ribosomal protein S6, which is rapidly 
phosphorylated by the S6 kinase when cells are stimulated to 
grow or divide.41 Indeed, we observed that increased expres-
sion of p-S6 in prechemotherapy tissue from MPM patients to 
be a prognostic factor influencing clinical outcome.23 In this 
study, we confirm the association of high p-S6 expression with 
a shorter PFS as previously reported.42 Interestingly, experi-
mental models using human mesothelioma cell lines grown as 
spheroids have shown p-S6 to contribute to acquired apoptotic 
resistance.43
To gain insight into the histopathological changes 
underlying the reduced expression of the PI3K/mTOR activity 
biomarkers evaluated herein after induction chemotherapy, we 
decided to investigate apoptosis and proliferation using two 
bona fide markers, cleaved caspase-3 and Ki-67. Interestingly, 
we found an increased cleaved caspase-3 apoptotic index and 
a decreased Ki-67 proliferative index in postchemotherapy 
specimens. Consistent with four previous reports, we found a 
high proliferation index before chemotherapy to be associated 
with a worse prognosis.44–47 Notably, our Ki-67 expression 
median scores were in close alignment with the MPM reports 
by Beer et al.44 and Kadota et al.45
The changes observed herein suggest a link between 
decreased cell proliferation coupled with increased apoptosis 
and modification of PI3K/mTOR pathway components. This 
is further supported by previous data from our laboratory 
assessed in a smaller subset of patients, where significantly 
increased terminal deoxynucleotidyl transferase–mediated 
deoxyuridine triphosphate-biotin nick end-labeling positivity 
was observed and where increased expression of the senes-
cence marker plasminogen activator-inhibitor-1 in MPM tis-
sue specimens collected after chemotherapy was associated 
with a worse clinical outcome.26 However, our analyses did 
not reveal any significant correlation between expression of 
PTEN, p-mTOR, and p-S6 with either cleaved caspase-3 or 
Ki-67 indices, even though PI3K/mTOR signaling is a key reg-
ulator of cell survival and apoptosis.48 This may be explained 
by different scoring methods applied (H-score approach for 
PI3K/mTOR activity markers versus hot spot labeling indices 
for Ki-67 and cleaved caspase-3). The percentage of positive 
tumor cells (labeling index) has been widely applied for the 
scoring of Ki-67 and apoptosis.27,28,49 Nevertheless, this method 
was inappropriate for assessing PI3K/mTOR activity markers 
as they were expressed in cytoplasmic and nuclear fractions of 
the majority of tumor cells with different degree of intensity 
(Fig. 1). In addition, it is more than likely that other molecules 
deregulated in MPM could account for the regulation of pro-
liferation and apoptosis besides PI3K/mTOR pathway. Future 
studies will be necessary to determine how PI3K/mTOR 
activity is modified by chemotherapy and its implication in 
the regulation of tumor cell survival. Nevertheless, these data 
suggest an ongoing response of tumor cells to chemotherapy 
confirming the reduced PI3K/mTOR signaling detected herein 
as a response mechanism to treatment which may ultimately 
impinge on patient survival.
There were limitations to the present study, including 
fewer numbers and less material of MPM patient samples pre-
chemotherapy as opposed to postchemotherapy. This resulted 
in a reduction in the relevant number of paired samples which 
may have limited statistical power. In addition, because MPM 
is a particularly heterogeneous type of tumor, it is possible 
that even up to four cores per patient do not fully represent 
the nature of the individual tumor. Moreover, despite the fact 
that both cohorts underwent a similar treatment regimen and 
were observed during a comparable period of time (i.e., 10 
years), one cannot ignore the bias that stems from the use of 
retrospective samples from different institutions, including 
the inability to control for all other factors (i.e., confounding 
variables), a limitation of all observational studies.
Thus, to summarize, pathway analysis using human 
MPM tumor TMAs may provide potentially significant infor-
mation as to the selection process of MPM patients undergoing 
induction chemotherapy for mesothelioma surgery or rather 
molecular-targeted therapy. Furthermore, these biomarkers 
might be useful to assist with the designing of effective clini-
cal trials. The novel data reported in the present study sug-
gest that dynamic changes in PTEN and p-mTOR expression 
during induction chemotherapy represent prognostic factors 
for MPM patients’ OAS. Multi-institutional efforts comprised 
larger cohorts will be necessary to validate our findings. Taken 
together, our data support a role for activation of PI3K/mTOR 
signaling in MPM, and support the growing evidence for the 
use of anticancer drugs that inhibit the PI3K/mTOR signaling 
pathway in the treatment of MPM.
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